Florida Cancer Specialists

Sarasota, Florida 37203

43 studies enrolling now · 143 studies all time

What they study most

ATC, Acinar Cell Carcinoma, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Adenoid Cystic Carcinoma, Advance Solid Tumors, Advanced Cancer, Advanced Hematologic Tumors, Advanced Lymphoma, Advanced Malignancies, Advanced Malignant Solid Tumors, Advanced Non-Small Cell Lung Cancer

Studies at this site

• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Recruiting now
• A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation — Recruiting now
• Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer — Recruiting now
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Recruiting now
• A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 — Recruiting now
• Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer — Recruiting now
• A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors — Recruiting now
• First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors — Recruiting now
• First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer — Recruiting now
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer — Recruiting now
• A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer — Recruiting now
• A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors — Recruiting now
• A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers — Recruiting now
• A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer — Recruiting now
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — Recruiting now
• A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation — Recruiting now
• A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors — Recruiting now
• Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — Recruiting now
• A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas — Recruiting now
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors — Recruiting now
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors — Recruiting now
• A Study of HLD-0117 in Patients With Metastatic Breast Cancer — Recruiting now
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — Recruiting now
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors — Recruiting now
• QTX3034 in Patients With KRAS G12D Mutation — Recruiting now
• A Study of DB-1310 in Advanced/Metastatic Solid Tumors — Recruiting now
• A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma — Recruiting now
• A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib — Recruiting now
• A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors — Recruiting now
• Study of AVZO-021 in Patients With Advanced Solid Tumors — Recruiting now
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies — Recruiting now
• Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies — Recruiting now
• Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies — Recruiting now
• A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer — Recruiting now
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL — Running, not enrolling
• A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer — Running, not enrolling
• Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors — Running, not enrolling
• A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer — Completed
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors — Stopped early
• PRO1107 in Patients With Advanced Solid Tumors — Stopped early
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) — Running, not enrolling